Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Medicare Advantage Stars Measures: Impact on Kidney Care Quality and Future Opportunities.

Journal of the American Society of Nephrology : JASN·2026
Same author

Real-Time CustomGPT Generated Feedback for Medical Students: A Simulation-Based Pilot Study.

Academic pediatrics·2026
Same author

Acute Liver Failure in a Patient with Myasthenia Gravis.

Gastroenterology·2026
Same author

Push pin induced artifact: A mimic of iron pill injury in gastrointestinal pathology.

Human pathology·2026
Same author

Evaluating the Impact of Intensive Care Unit Rotations During the Pediatric Clerkship.

Medical science educator·2026
Same author

Precision genomic profiling in Gaucher disease: insights from atypical presentations.

Frontiers in genetics·2025

Related Experiment Video

Updated: Jun 21, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Mycophenolate mofetil-induced colitis in children.

Uma Padhye Phatak1, Patricia Seo-Mayer, Dhanpat Jain

  • 1Yale University School of Medicine, New Haven, CT 06520, USA.

Journal of Clinical Gastroenterology
|July 18, 2009
PubMed
Summary

Severe colitis from Mycophenolate Mofetil (MMF) is rare in children. This report details two pediatric cases, emphasizing MMF-induced colitis as a critical diagnosis for diarrhea in transplant patients.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: Jun 21, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

  • Pediatric Nephrology
  • Gastroenterology
  • Transplant Medicine

Background:

  • Mycophenolate Mofetil (MMF) is a standard immunosuppressant in pediatric renal transplantation.
  • Gastrointestinal side effects are common, but severe colitis is considered rare and primarily documented in adults.

Observation:

  • Two pediatric renal transplant recipients developed severe colitis.
  • Infectious and other etiologies for diarrhea were excluded.
  • Histologic findings varied, mimicking inflammatory bowel disease and graft-versus-host disease.

Findings:

  • Mycophenolate Mofetil (MMF)-induced colitis was diagnosed in both pediatric patients.
  • Discontinuation of MMF led to complete symptom resolution, establishing a likely causal link.
  • Histological diversity was noted in colonic biopsies.

Implications:

  • These cases highlight the importance of considering MMF-induced colitis in pediatric transplant patients presenting with diarrhea.
  • Early recognition and MMF withdrawal can prevent severe complications.
  • Further investigation into MMF's gastrointestinal effects in pediatric populations is warranted.